Clinical Trial Update: A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia [Phase 3]

View source ↗

Summary

A Phase III study evaluating satavaptan versus placebo in patients with dilutional hyponatremia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyponatremia
• Syndrome of Inappropriate Antidiuretic Hormone Secretion

Drugs mentioned

• Satavaptan (satavaptan)

Snippet

Sponsor: Sanofi | Conditions: Hyponatremia, Inappropriate ADH Syndrome | Phase 3 | Status: TERMINATED